AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25908462 — intervention group
Group type: EXPERIMENTAL
Intervention: CHHIPS - BP-lowering intervention
Number of subjects: 942
Study 23417664 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 166
Study 23417664 — intervention group
Group type: COMPARATOR
Intervention: Group Care (GC)
Number of subjects: 166
Study 22590838 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Metformin (500 mg tablets, two per twelve hours)
Number of subjects: 100
Study 22590838 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin + Metformin
Number of subjects: 100
Study 22590838 — intervention group
Group type: COMPARATOR
Intervention: Insulin + Placebo
Number of subjects: 100
Study 19541717 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular chest physiotherapy
Number of subjects: 20
Study 19541717 — intervention group
Group type: COMPARATOR
Intervention: No chest physiotherapy
Number of subjects: 20
Study 16905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (6x weekly)
Number of subjects: 121
Study 16905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (3x weekly)
Number of subjects: 121
Study 16905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (once weekly)
Number of subjects: 121
Study 16905220 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin treatment
Number of subjects: 121
Study 15534928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole
Number of subjects: 102
Study 15534928 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 102
Study 11728145 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK‐tPA
Number of subjects: 16949
Study 11728145 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA
Number of subjects: 16949
Study 9158573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group outpatient visits (n = 160)
Number of subjects: 321
Study 9158573 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 161)
Number of subjects: 321
Study 7713125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endopyelotomy
Number of subjects: 46
Study 7713125 — intervention group
Group type: COMPARATOR
Intervention: Pyeloplasty
Number of subjects: 46
Study 31798953 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy (hand osteoarthritis education, assistive devices, CMCJ orthoses, and exercises)
Number of subjects: 180
Study 31798953 — intervention group
Group type: COMPARATOR
Intervention: Control group (only hand osteoarthritis information)
Number of subjects: 180
Study 31798953 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 180
Study 31798953 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 29974634 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin as an adjunct to compression therapy
Number of subjects: 0
Study 29974634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26248498 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + EAA
Number of subjects: 8
Study 24857251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 223
Study 24857251 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 223
Study 22441863 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in the trauma room
Number of subjects: 1124
Study 22441863 — intervention group
Group type: COMPARATOR
Intervention: CT in the radiology department
Number of subjects: 1124
Study 22441863 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in the trauma room (multiple trauma subgroup)
Number of subjects: 1124
Study 22441863 — intervention group
Group type: EXPERIMENTAL
Intervention: CT in the trauma room (TBI subgroup)
Number of subjects: 1124
Study 21322823 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine therapy
Number of subjects: 25
Study 19128556 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic surgeons
Number of subjects: 60
Study 19128556 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 60
Study 15797646 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 128
Study 15797646 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 128
Study 12182952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of glucose
Number of subjects: 14
Study 12182952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of fat
Number of subjects: 14
Study 12182952 — intervention group
Group type: COMPARATOR
Intervention: Comparison between lean and obese subjects
Number of subjects: 14
Study 10359029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 1000 mg/m2/d
Number of subjects: 67
Study 10359029 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA), 2 mg/kg on the first post-operative day
Number of subjects: 67
Study 8557012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium (9.9 +/- 1.3 micrograms kg-1 min-1)
Number of subjects: 30
Study 8557012 — intervention group
Group type: COMPARATOR
Intervention: Intermittent boluses of rocuronium (6.4 +/- 2.3 micrograms kg-1 min-1)
Number of subjects: 30
Study 8557012 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of rocuronium
Number of subjects: 30
Study 8557012 — intervention group
Group type: COMPARATOR
Intervention: Surgical patients receiving comparable infusions
Number of subjects: 30
Study 1785004 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (40 Gy) followed by cystectomy
Number of subjects: 183
Study 1785004 — intervention group
Group type: COMPARATOR
Intervention: Radical irradiation (60 Gy) followed by salvage cystectomy
Number of subjects: 183
Study 1785004 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cystectomy
Number of subjects: 183
Study 1785004 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 183
Study 1785004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystectomy
Number of subjects: 183
Study 1785004 — intervention group
Group type: EXPERIMENTAL
Intervention: Late complications
Number of subjects: 183
Study 7013307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (refined sugar excluded)
Number of subjects: 20
Study 7013307 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (refined sugar-rich)
Number of subjects: 20
Study 29738405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group aerobic and strength training (twice weekly for 24 weeks, 60 minutes each session using ankle weights, latex resistance bands, and dumbbells)
Number of subjects: 52
Study 29738405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 52
Study 30156654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with essential oils of lavender and geranium at 1% concentration, six sessions
Number of subjects: 0
Study 30156654 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26813471 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of valsartan (group B)
Number of subjects: 86
Study 26813471 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of valsartan combined with tacrolimus (group C)
Number of subjects: 86
Study 26813471 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose of valsartan (group A)
Number of subjects: 86
Study 25415738 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic tracking
Number of subjects: 50
Study 21416557 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT)
Number of subjects: 25
Study 21416557 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 25
Study 20352259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy + irrigation of gallbladder bed with 20 mL 0.5% bupivacaine solution
Number of subjects: 30
Study 20352259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy + irrigation of gallbladder bed with bupivacaine + 10 mL 0.5% bupivacaine solution every 6 h
Number of subjects: 30
Study 20352259 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 30
Study 17606880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 500 mg once daily for 4 days combined with oral prednisone 60 mg once daily for 5 days (n = 16)
Number of subjects: 35
Study 17606880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 35
Study 17606880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide and prednisone (treatment group)
Number of subjects: 35
Study 15658142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 30
Study 15658142 — intervention group
Group type: COMPARATOR
Intervention: Plain radiographs
Number of subjects: 30
Study 11881887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp CVP (central venous pressure guided fluid challenges)
Number of subjects: 90
Study 11881887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp DOP (oesophageal Doppler ultrasonography guided fluid challenges)
Number of subjects: 90
Study 11881887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp CVP
Number of subjects: 90
Study 11881887 — intervention group
Group type: EXPERIMENTAL
Intervention: Gp DOP
Number of subjects: 90
Study 11881887 — intervention group
Group type: COMPARATOR
Intervention: Gp CON
Number of subjects: 90
Study 11881887 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 90
Study 10458232 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with ifosfamide/etoposide on days 1-3 and cyclophosphamide/doxorubicin on day 5, followed by granulocyte colony-stimulating factor; maintenance included four alternating cycles of ifosfamide/etoposide and doxorubicin/CTX.
Number of subjects: 53
Study 10458232 — intervention group
Group type: COMPARATOR
Intervention: CTX dose levels during maintenance (two arms).
Number of subjects: 53
Study 10458232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen including dose-intensification.
Number of subjects: 53
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with minimal counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with minimal counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with individual counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with individual counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with group counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with group counseling
Number of subjects: 504
Study 7563558 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact treatment
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy
Number of subjects: 504
Study 7563558 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy
Number of subjects: 504
Study 2348582 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion group (ICT or PTCA)
Number of subjects: 16
Study 2348582 — intervention group
Group type: COMPARATOR
Intervention: Non-reperfusion group
Number of subjects: 16
Study 115801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal self‐administration of an aqueous solution of a glutaraldehyde‐treated timothy grass pollen allergen
Number of subjects: 12
Study 115801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30540715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV TXA) 2g (1g before incision and 1g before wound closure)
Number of subjects: 83
Study 30540715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (PO TXA) 1.95g 2 hours preoperatively
Number of subjects: 83
Study 30540715 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IV TXA and PO TXA
Number of subjects: 83
Study 30218546 — intervention group
Group type: EXPERIMENTAL
Intervention: EM fungal OTUs at colder sites
Number of subjects: 75
Study 30218546 — intervention group
Group type: EXPERIMENTAL
Intervention: EM fungal richness at colder sites
Number of subjects: 75
Study 30218546 — intervention group
Group type: EXPERIMENTAL
Intervention: EM fungal OTUs composition
Number of subjects: 75
Study 30218546 — intervention group
Group type: EXPERIMENTAL
Intervention: EM fungal OTUs restricted to low mean annual temperatures
Number of subjects: 75
Study 27236888 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 0.5 g each pill, three pills each time, 3 times per day for 3 months
Number of subjects: 59
Study 27236888 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 3 months
Number of subjects: 59
Study 27236888 — intervention group
Group type: COMPARATOR
Intervention: Comparison between XFC and SASP
Number of subjects: 59
Study 25256187 — intervention group
Group type: EXPERIMENTAL
Intervention: BDD-NET (therapist-supported, Internet-based cognitive-behavioral therapy) for 12 weeks
Number of subjects: 23
Study 25256187 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcome measures (depression, global functioning, quality of life)
Number of subjects: 23
Study 22493419 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg loading dose followed by 2 mg weekly)
Number of subjects: 121
Study 22493419 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg orally daily)
Number of subjects: 121
Study 22493419 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib (1,000 mg orally daily)
Number of subjects: 121
Study 22493419 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group not explicitly defined)
Number of subjects: 121
Study 20138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (APCam01)
Number of subjects: 19
Study 20138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop delivery after rapidly absorbed meals (APCam02)
Number of subjects: 19
Study 20138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (APCam03)
Number of subjects: 19
Study 20138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop delivery (pooled data)
Number of subjects: 19
Study 20138357 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop delivery
Number of subjects: 19
Study 17179256 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol at 0.1 mg/kg infused 4 min before intubation in normotensive patients
Number of subjects: 88
Study 17179256 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol at 0.2 mg/kg in hypertensive patients
Number of subjects: 88
Study 17179256 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl at 2 μg/kg
Number of subjects: 88
Study 17179256 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (any dose)
Number of subjects: 88
Study 15908277 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking and resistance exercise program
Number of subjects: 24
Study 15908277 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 12488239 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (10 mg twice daily)
Number of subjects: 51
Study 12488239 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine (20 mg daily)
Number of subjects: 51
Study 12488239 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine-XR (75 mg daily)
Number of subjects: 51
Study 12488239 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 10629348 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus aspirin
Number of subjects: 313
Study 10629348 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase alone
Number of subjects: 313
Study 9121851 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hourly CPT
Number of subjects: 63
Study 9121851 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hourly CPT
Number of subjects: 63
Study 9121851 — intervention group
Group type: COMPARATOR
Intervention: No CPT
Number of subjects: 63
Study 9121851 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study 1292072 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg capsule three times daily
Number of subjects: 60
Study 1292072 — intervention group
Group type: COMPARATOR
Intervention: Control group (multiple-vitamin tablet three times daily)
Number of subjects: 60
Study 1292072 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60
Study 1292072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 3966421 — intervention group
Group type: COMPARATOR
Intervention: 0 mg PN X HCl
Number of subjects: 0
Study 3966421 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg PN X HCl
Number of subjects: 0
Study 3966421 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.0 mg PN X HCl
Number of subjects: 0
Study 3966421 — intervention group
Group type: EXPERIMENTAL
Intervention: 20.0 mg PN X HCl
Number of subjects: 0
Study 30710185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapha® system application by the participant and a health professional at home
Number of subjects: 15
Study 30710185 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapha® system applied by the participant at home
Number of subjects: 15
Study 30710185 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol used in Brazil performed by a health professional at the hospital
Number of subjects: 15
Study 27926661 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin infusion (1.0 ng/kg/min)
Number of subjects: 0
Study 27926661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0
Study 24373022 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian inserted mini-implants
Number of subjects: 21
Study 24373022 — intervention group
Group type: COMPARATOR
Intervention: Control group (median mini-implants of the same size)
Number of subjects: 21
Study 26054362 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Self-Regulation Questionnaire (SSRQ)
Number of subjects: 834
Study 26054362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation Questionnaire (SRQ)
Number of subjects: 834
Study 23286722 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes sun exposure
Number of subjects: 6
Study 23286722 — intervention group
Group type: COMPARATOR
Intervention: 40 minutes sun exposure
Number of subjects: 6
Study 19286168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Group Triple P - Positive Parenting Program
Number of subjects: 75
Study 19286168 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 75
Study 17084676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 138
Study 15076779 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia (lidocaine injected into the anterior talofibular and calcaneofibular ligament, 1.5 cc each)
Number of subjects: 14
Study 15076779 — intervention group
Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 14
Study 11818693 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone or in combination with ribavirin
Number of subjects: 27
Study 11818693 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 non-IDUs)
Number of subjects: 27
Study 9803049 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged transdermal fentanyl (FENtd)
Number of subjects: 48
Study 8087191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium-adsorbed pertussis vaccine
Number of subjects: 49
Study 8087191 — intervention group
Group type: COMPARATOR
Intervention: Non-adsorbed pertussis vaccine
Number of subjects: 49
Study 8087191 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component vaccine as primary immunization
Number of subjects: 49
Study 8087191 — intervention group
Group type: COMPARATOR
Intervention: Monocomponent vaccine as primary immunization
Number of subjects: 49
Study 8087191 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE levels
Number of subjects: 49
Study 2676440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg twice a day)
Number of subjects: 28
Study 2676440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 855889 — intervention group
Group type: COMPARATOR
Intervention: Patient information package insert (FDA version)
Number of subjects: 253
Study 855889 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information brochure (study's version)
Number of subjects: 253
Study 31181179 — intervention group
Group type: EXPERIMENTAL
Intervention: DT‐BCTQ (Decision Tree Boston Carpal Tunnel Questionnaire)
Number of subjects: 4470
Study 31181179 — intervention group
Group type: EXPERIMENTAL
Intervention: DT‐BCTQ
Number of subjects: 4470
Study 27765695 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU daily
Number of subjects: 21
Study 27765695 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU weekly
Number of subjects: 21
Study 26437499 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Oil (EO) mouthrinse
Number of subjects: 165
Study 26437499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% Cetylpyridinium Chloride (CPC) mouthrinse
Number of subjects: 165
Study 26437499 — intervention group
Group type: COMPARATOR
Intervention: Control (5% hydroalcohol solution)
Number of subjects: 165
Study 24971679 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT after 55 min of cycle‐ergometer exercise at 60% VO2peak
Number of subjects: 10
Study 24971679 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT after 55 min of cycle‐ergometer exercise at 60% VO2peak
Number of subjects: 10
Study 23151156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 755